Funding rounds, M&A, IPOs, and market analysis—where capital is flowing and why the tape moves.
GoodRx has introduced GoodRx Employer Direct, a novel program enabling employers to subsidize the cost of expensive brand medications without impacting health insurance benefits, targeting high-cost drugs like GLP-1s.
GoodRx has introduced GoodRx Employer Direct, a novel program enabling employers to subsidize the cost of expensive brand medications without impacting health insurance benefits, targeting high-cost drugs like GLP-1s.
READ MORE
Generate Biomedicines recently completed a significant Initial Public Offering (IPO), raising $400 million to finance pivotal clinical trials for their innovative severe asthma drug.
The BioSpace team reports from the J.P. Morgan Healthcare Conference in San Francisco, providing a detailed overview of the latest trends and developments in the healthcare and biopharma sectors.
Coral Care recently raised $13 million in a Series A funding round to expand its in-home pediatric therapy offerings, supported by a syndicate of notable venture capital firms.
The ongoing crisis in rural healthcare, marked by the potential closure of hundreds of hospitals, threatens not only public health outcomes but also the economic stability of rural communities across America.
Hims & Hers’ acquisition of Eucalyptus for $1.15 billion marks a significant step towards global expansion and revenue diversification at a time of heightened regulatory scrutiny in the U.S. GLP-1 space.
Rainfall Health has raised $15 million in a Series A funding round to assist hospitals in adapting to new Centers for Medicare & Medicaid Services (CMS) healthcare models. This funding highlights ongoing innovation in hospital administration amidst evolving regulatory frameworks.
Frist Cressey Ventures has closed a $425 million fund focusing on early-stage healthcare companies using AI to improve care and support aging populations.
Solera Health has established a new behavioral health network collaborating with Calm Health and Lyra Health to provide integrated digital mental health solutions.
Capital allocation in biopharma venture capital in 2025 heavily favored later-stage clinical companies, leaving early-stage biotechs to suffer a decline in funding. This trend reflects the growing risk aversion among investors in the current economic climate.
Medicare Advantage membership growth has slowed down for the second year in a row as major insurers adjust to significant changes in the program. This trend raises questions about the future dynamics in the Medicare Advantage market.
